Novel Applications of MICA-Binding Fusion Molecules

Publication ID: 24-11857571_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Novel Applications of MICA-Binding Fusion Molecules,” Published Technical Disclosure No. 24-11857571_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857571_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,571.

Summary of the Inventive Concept

This inventive concept leverages the core technology of anti-MICA antigen binding fragments to address pressing issues in water quality, skin conditions, respiratory diseases, agriculture, and food safety, opening up new avenues for innovation and commercialization.

Background and Problem Solved

The original patent disclosed anti-MICA antigen binding fragments, fusion molecules, cells, and methods of using them, primarily focused on natural killer cells and cancer therapy. However, the patent's limitations in terms of applicability and scope hindered its potential in other fields. This inventive concept solves this problem by applying the core technology to entirely new industries and use cases, capitalizing on the versatility and adaptability of MICA-binding fusion molecules.

Detailed Description of the Inventive Concept

The new claims encompass a system for monitoring and controlling water quality, a method for reducing inflammation in skin conditions, a device for diagnosing and treating respiratory diseases, a method for enhancing crop yields, and a system for detecting and preventing foodborne illnesses. Each of these applications leverages the MICA-binding fusion molecule's ability to detect and neutralize specific targets, providing innovative solutions to pressing problems in their respective fields.

Novelty and Inventive Step

The novelty of this inventive concept lies in its application of the anti-MICA antigen binding fragments to entirely new industries and use cases, demonstrating an inventive step beyond the original patent's scope. The new claims introduce unexpected and non-obvious uses for the core technology, expanding its potential for commercialization and impact.

Alternative Embodiments and Variations

Alternative embodiments of this inventive concept could include the development of MICA-binding fusion molecules with tailored specificity for different applications, the integration of these molecules with existing technologies, or the exploration of new delivery methods and formulations. Variations could involve adapting the core technology to address related problems within each industry, such as using MICA-binding fusion molecules to detect and treat other waterborne pathogens or to monitor and control air quality.

Potential Commercial Applications and Market

The commercial potential of this inventive concept is vast, with applications in water quality management, skin care, respiratory disease diagnosis and treatment, agriculture, and food safety. The target industries include water treatment, pharmaceuticals, medical devices, agriculture, and food processing, with potential partnerships and collaborations with companies, research institutions, and government agencies.

Field of Art

Biotechnology and immunological engineering, focusing on antigen binding fragments, chimeric antigen receptors (CARs), and molecular targeting strategies for cellular interactions

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or bioengineering, experienced in antibody engineering, receptor interactions, and therapeutic molecule design, familiar with techniques for modifying protein binding domains and exploring novel applications of targeted molecular technologies

Obviousness Rationale

A person having ordinary skill in the art would recognize that the MICA-binding fusion molecule's core technology from the source patent provides a versatile platform for developing targeted interventions across multiple domains. The fundamental mechanism of specific molecular binding can be readily adapted to different environmental and biological contexts by applying standard biotechnological techniques. The PTD's variations represent predictable extensions of the original molecular targeting strategy, utilizing well-established principles of protein engineering and receptor interactions.

Obvious Combinations & Variations

Source Patent Element
Anti-MICA antibody fragment with specific binding capabilities
PTD Variation
Water quality monitoring system using MICA-binding fusion molecule to detect pathogens
Obviousness Reasoning
Predictable application of molecular detection principles, extending known receptor binding techniques to environmental monitoring using standard biosensor development methodologies
Source Patent Element
Chimeric antigen receptor (CAR) targeting MICA-expressing cells
PTD Variation
Respiratory disease diagnostic device detecting MICA-expressing cells in lung tissue
Obviousness Reasoning
Logical extension of cellular targeting technology, applying existing molecular recognition principles to diagnostic imaging and therapeutic intervention strategies
Source Patent Element
Antigen binding fragment with modular protein engineering approach
PTD Variation
Agricultural application for neutralizing plant pathogens using MICA-binding fusion molecules
Obviousness Reasoning
Routine adaptation of molecular targeting technology to alternative biological systems, utilizing known protein engineering techniques to modify binding specificity
Source Patent Element
Single chain variable fragment (scFv) with flexible linker configuration
PTD Variation
Skin inflammation reduction method targeting MICA-expressing immune cells
Obviousness Reasoning
Predictable therapeutic approach leveraging established immunomodulatory molecular engineering principles, representing a straightforward application of known receptor interaction strategies
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in the Published Technical Disclosure (PTD) would have been obvious to a person having ordinary skill in the art at the time of invention, given the teachings of US Patent 11857571. The PTD demonstrates that the core molecular targeting technology of the source patent can be readily adapted across multiple technological domains through routine biotechnological engineering techniques, thereby rendering subsequent claims involving similar molecular strategies prima facie obvious.

Original Patent Information

Patent NumberUS 11,857,571
TitleAnti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
Assignee(s)The Trustees of Dartmouth College